Study Technical and Cost Analysis for the Implementation of a Recycling Plant of (NFU) in the State of Tlaxcala

2018 ◽  
Vol 4 (5) ◽  
pp. 1-5
Author(s):  
José Tapia Sánchez ◽  
Alejandra Torres López ◽  
Elizabeth Montiel Huerta
Keyword(s):  
2010 ◽  
Author(s):  
Khalifa Al Khalifa ◽  
Hamouda Abdel Magid

Author(s):  
Василий Владимирович Чекмарев ◽  
Владимир Васильевич Чекмарев

Целью статьи является формулирование дополнительных аргументов необходимости повышения эффективности институционализации процессов устойчивого развития экономической системы страны и обеспечения социально-экономической безопасности государства и общества. Методологически предъявляемая авторская позиция базируется на сочетании позитивного и нормативного принципов, использовании инструментов статистического и функционально-стоимостного анализа. Новизной результатов проведённого исследования является обоснование предложений по реорганизации функций экономического блока управления государственным развитием, дополняющих идеи академика РАН С.Ю. Глазьева. Приращением научного знания декларируется развитие теории экономической безопасности на основании формулирования тезисов об общественном контроле процессов обеспечения социально-экономической безопасности общества и государства. The purpose of the article is to formulate additional arguments on the need to increase the effectiveness of institutionalizing the processes of sustainable development of the country's economic system and ensuring the socio-economic security of the state and society. The methodologically presented author's position is based on a combination of positive and normative principles, the use of statistical and functional-cost analysis tools. The novelty of the results of the study is the justification of proposals for the reorganization of the functions of the economic block of state development management, supplementing the ideas of academician of the Russian Academy of Sciences S.Yu. Glazyev. An increase in scientific knowledge declares the development of the theory of economic security on the basis of the formulation of theses on public control of the processes of ensuring the socio-economic security of society and the state.


2000 ◽  
Vol 24 (6) ◽  
pp. 609-634 ◽  
Author(s):  
Michael T. French ◽  
Helena J. Salomé ◽  
Antoinette Krupski ◽  
James R. Mckay ◽  
Dennis M. Donovan ◽  
...  

2020 ◽  
Vol 36 (S1) ◽  
pp. 44-44
Author(s):  
Alona Masheiko ◽  
Oresta Piniazhko ◽  
Iryna Romanenko ◽  
Mariya Leleka ◽  
Valeriia Serediuk

IntroductionThe Health Technology Assessment (HTA) Department of the “State Expert Center of the Ministry of Health (MoH) of Ukraine” was established in 2019 for conducting assessments and development of recommendations for informing decisions for the Ministry of Health of Ukraine (MoH) regarding the financing of health technologies based on HTA. The study aimed to conduct cost analysis and compare the treatment costs of two available dosage forms of tocilizumab for subcutaneous and intravenous administration for systemic juvenile idiopathic arthritis in Ukraine. Currently there is a central procurement program financed by the state budget with pharmaceuticals provided to patients with juvenile idiopathic arthritis approved by the Cabinet of Ministers Decree of Ukraine №255 dated 13.03.2019.MethodsThe cost analysis was carried out for tocilizumab over a 1-year horizon per one patient. The analysis included drug manufacturers' prices from the registry of the MoH dated 19.09.2019. The annual number of tocilizumab vials for intravenous infusion for each weight category of patients is approved by the order MoH №334 from 14 February 2019. The direct medical costs were included in the analysis omitting cost of administration.ResultsThe direct medical costs of treatment with intravenous tocilizumab per one patient for one budgetary year ranged from between USD7,563.83 and USD30,255.30 depending on patient's weight that was in the range of 10–80 kg. The direct medical costs of treatment per one patient for one year with subcutaneous tocilizumab was USD7,782.40 for patients < 30 kg and USD15,564.80 for patients ≥ 30 kg.ConclusionsThe introduction of subcutaneous tocilizumab can potentially lead to cost savings on average USD 4,041.97 (34.2%) for patients < 30 kg and USD 5,245.82 (25.2%) for patients ≥ 30 kg per one patient for 1-year treatment compared to the intravenous route. Intravenous tocilizumab has an economic advantage over the subcutaneous route solely for the pediatric population of certain weight categories. The cost of intravenous tocilizumab was USD 218.58 lower (2.9%) for patients ≤ 13 kg and USD 2,320.25 lower (17.5%) for patients with weight 31–35 kg, compared to the cost of subcutaneous tocilizumab.


Sign in / Sign up

Export Citation Format

Share Document